Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET
Company Participants
David Nakasone - Head, IR
Bobak Azamian - Chairman, CEO
Aziz Mottiwala - CCO
Jeff Farrow - CFO, CSO
Conference Call Participants
Jason Gerberry - Bank of America
Eddie Hickman - Guggenheim Securities
Oren Livnat - H.C. Wainwright
Frank Brisebois - Oppenheimer
Operator
Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.
At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations to lead off the call. Please begin.
David Nakasone
Thank you. Before we begin, I encourage everyone to go to the Investors Section of the Tarsus website to view the earnings release and related financial tables we will be discussing today.
Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer.
I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.
With that, I'll turn the call over to Bobby. Bobby?
Bobak Azamian
Thank you, Dave, and thank you all for joining us for our first ever earnings call, and our first opportunity to speak with you since the highly anticipated launch of XDEMVY, the only FDA approved treatment for Blepharitis. We are off to a great start and I'm pleased to share our progress with you today. Blepharitis is a pervasive and damaging eyelid disease that affects approximately 25 million Americans. Of these more than 7 million are seeking treatment for a complimentary eye condition. Double clicking on that number, more than 1.5 million people have already been diagnosed with arthritis and are highly motivated to find an effective treatment. As anticipated, this is the patient segment driving strong initial demand, and as the XDEMVY launch progresses, we expect to expand further into that group of 7 million patients. XDEMVY was approved a month ahead of its scheduled PDUFA date, and as planned, we made sure it was available to patients within a month of approval.